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We herein report upon an approach whereby the interpretation of tandem mass spectrometry
spectra can be both expedited and simplified via the accurate mass assignment of product ions
utilizing a tandem quadrupole time-of-flight mass spectrometer (QqTOF). The applicability of
the QqTOF in the drug metabolism laboratory is illustrated by the elucidation and differen-
tiation of the dissociative pathways for Bosentan and its hydroxylated and demethylated
metabolites. Target analyte fragmentation mechanisms were readily achieved by the measure-
ment of product ions with a mass accuracy ,5 ppm, possible by single-point internal
recalibration using the residual precursor ion as calibrant. Differentiation of both precursor
and product ions from nominally isobaric matrix species derived from biological extracts is
demonstrated by operation of the QqTOF at resolutions of ;8000 (m/DmFWHM). (J Am Soc
Mass Spectrom 1999, 10, 1305–1314) © 1999 American Society for Mass Spectrometry
Mass spectrometry with atmospheric pressureionization, in particular electrospray ioniza-tion, has become an essential and recognized
tool for both pharmacokinetic investigations and drug
metabolism studies. Most often, collision induced dis-
sociation (CID) techniques such as those offered by
triple-stage quadrupole and quadrupole ion trap mass
spectrometry are applied towards the characterization
of drug biotransformation products [1–3]. However,
difficulties may occur in the interpretation of CID
spectra originating from three possible primary sources:
(i) the structural rearrangement of fragment ions tran-
spires in fashions not readily rationalized, (ii) compet-
itive fragmentation occurs whereby a precursor ion
experiences multiple decomposition pathways result-
ing in spectra containing overlapping lineage, and (iii)
the occurrence of isobaric parent ions of differing struc-
ture results in overlapping, and therefore convoluted,
product ion spectra.
Mass spectrometric techniques offering multiple
stages of mass spectrometry (i.e., MSn, where n . 2) are
often used to facilitate CID spectral interpretation, be-
cause they allow for the establishment of ion lineage.
Ion traps allow selective precursor ion isolation for each
stage of mass spectrometry, whereas triple-stage quad-
rupoles employing CID in the atmosphere to vacuum
transition region produce data containing information
somewhat analogous to MS3, albeit with less selectivity.
However, neither instrument currently has the capabil-
ity to routinely assign, with high resolution, accurate
product ion mass in order to establish elemental com-
position.
Until the advent of the hybrid quadrupole time-of-
flight mass spectrometer [4, 5], or QqTOF, few instru-
ments provided at a reasonable cost the capability of
accurate product ion mass assignment. Because the
mass accuracy of each of the triple-stage quadrupole,
quadrupole ion trap, and magnetic sector is limited by
the imposition of electric fields which vary during a
mass scan, the inclusion of several internal reference
ions is required in order to achieve mass accuracy in the
low ppm (parts-per-million) range. As mass measure-
ment with a time-of-flight analyzer is virtually simulta-
neous, and because all ions are exposed to constant
electric fields, mass calibration is linear over a broad
dynamic range [6]. As a result, only two reference ions
of known mass are required to calibrate a spectrum
spanning several hundred Daltons [an advantage not
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fully applicable to matrix-assisted laser desorption/
ionization (MALDI) TOF instruments with delayed
extraction and/or postsource decay]. Once the calibra-
tion curve is established, only a single reference point is
required to correct the slope of the line in order to adjust
for drift; slope correction is possible by utilizing the
residual precursor ion to calibrate an entire product ion
spectrum. Product ion mass assignment with an accu-
racy ,5 ppm is attainable when the precursor ion mass
can be determined via calculation from its elemental
composition. In the absence of precursor ion elemental
composition information, precursor mass may be deter-
mined in the full scan mode using added internal
calibrants; this measured mass may then be used for the
recalibration of the product ion spectrum. However,
associated with such independent measurements is the
propagation of error such that product ion mass accu-
racy is diminished by a factor of ;=2. Regardless of the
nature by which precursor ion mass is determined, the
necessity exists for the requirement of an internal ref-
erence ion to compensate for long term mass calibration
drift as a consequence of temperature fluctuations
which can cause changes in flight tube length and
applied voltage. Occasional external recalibration (dai-
ly) is sufficient to maintain mass accuracy within 30
ppm.
High resolution helps to improve the mass accuracy
by increasing the assurance that the mass of the ion to
be measured is not skewed by an underlying interfer-
ence. TOF instruments with orthogonal extraction op-
tics designed to accommodate continuous flow ion
sources are demonstrating routine resolution capabili-
ties in the 5000–10,000 (m/DmFWHM) range [4, 5, 7, 8], a
significant improvement over quadrupoles and ion
traps that typically operate at a resolution of ;3 3
mass [9]; notably, both sector and ion cyclotron reso-
nance (ICR) configurations are superior to the current
commercially available TOF instruments in this regard.
The answer to the commonly posed question: “How
much resolution is sufficient to offer reasonable assur-
ance of accurate mass measurement?” remains unan-
swered because it is highly dependent upon chemical
background and target mass, both of which are vari-
ables [13]. However, it may be demonstrated that a
resolution in excess of 100,000 would be required when
working in the 100–500 Da range in order to resolve
interferences from target analytes differing by 61 mDa
(m/DmFWHM 5 100/0.001). In the MS/MS mode, virtu-
ally all chemical interference is removed from the
product ion spectrum with the exception of the mass
window transmitted around the precursor ion. Since
the product ion spectrum is calibrated from the precur-
sor ion, error propagation may occur unless the precur-
sor ion is free of chemical interference.
A key goal in the current research effort was to
explore the utility of operation in the intermediate
resolution range (i.e., 5000–10,000) for accurate mass
measurement of target analytes in sample matrices
which typify those conditions under which drug me-
tabolite structure identification is performed. As a
means of illustrating the efficacy with which accurate
product ion mass measurements may be utilized in
drug metabolism studies, the structural features of key
product ions derived from the dissociation of the endo-
thelin receptor antagonist Bosentan (Ro 47-0203) and
associated metabolites (Figure 1) were studied by direct
infusion of plasma and bile extracts into an electrospray
ionization source. In a previous study, a laborious and
extensive investigation was required to elucidate the
fragment ion structures of Bosentan using deuterium
exchange reactions, pseudo-MS3 studies, and exact
mass determinations from a sector instrument [10]. In
the study reported here, we demonstrate the degree to
which finding solutions to such structural problems can
be accelerated and rationalized by employing the high
resolution and accurate mass measurement capabilities
of the QqTOF.
Experimental
Materials and Reagents
Mass calibration standards CsI and the peptide
ALILTLVS were obtained from commercial sources
(Sigma Chemical, St. Louis, MO), whereas Bosentan and
all associated metabolites were prepared in-house.
HPLC grade reagents were used for all biological ex-
tractions and to prepare standard solutions. Mass cali-
brants were dissolved in 1:1 (v/v) methanol/water
containing 1% acetic acid, whereas Bosentan and me-
tabolite standards were prepared in 1:1 (v/v) acetoni-
trile/water containing 0.1% formic acid.
Sample Preparation
Following the oral administration of Bosentan, 500 mL
aliquots each of plasma and bile were collected and the
metabolites of Bosentan extracted with 2500 mL 4:1
chloroform:isopropanol. The extracts were reconsti-
tuted with 200 mL of 70:30 H2O:CH3CN (5 mM
NH4OAc), diluted 103 with 50:50 CH3CN:H2O (0.1%
HCO2H), and directly infused into the ion source of the
QqTOF. The infused concentration range of the com-
bined parent drug and metabolic products was 15–300
pg/mL and 50–950 ng/mL, for plasma and bile extracts,
respectively. Standard solutions were introduced at a
concentration of 1 ng/mL.
Mass Spectrometry
The QqTOF instrument used in the current investiga-
tion was a prototype constructed from a PE-Sciex API
365 triple-stage quadrupole platform with an orthogo-
nally oriented TOF mass analyzer substituted for Q3
(Figure 2). Details of the QqTOF architecture have been
presented elsewhere [5], and so herein are only briefly
described. The pre-TOF ion path consists of three quad-
rupoles: Q0, Q1, and Q2. Q0 and Q2 function as rf-only
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quadrupoles and thus serve as ion guides. When the
QqTOF is operated in a full scan mode, Q1 also acts as
an rf-only bandpass filter with the optimal rf voltage
dependent upon the specified mass range. When a mass
range greater than a factor of 10 was required, the rf
voltage was modulated (stepped between two or more
rf levels) and each transmission window received an
equivalent amount of dwell time. Tandem mass spec-
trometric measurements were achieved by operating
Q1 in a resolving mode with 1 and 3 Da transmission
windows for standard solutions and biological extracts,
respectively. Argon collision gas was present in the
collision cell (2) for both full scan and product ion
measurements. In the former, collision energy (in the
laboratory frame) was ,11 eV in order to minimize
fragmentation, whereas all product ion spectra were
acquired using a collision energy of 30 eV. The presence
of collision gas in both full scan and MS/MS modes was
required in order to collisionally cool (thermalize) ions
such that both spatial and kinetic energy distributions
were minimized, thereby improving ion transmission
efficiency and peak resolution [11, 12].
Ions exiting Q2 are re-accelerated to ;9 eV/charge.
They are then focused through a slit (4) by a grid (3) into
the ion storage modulator (5). At the beginning of the
injection cycle, the TOF storage modulator is initially
field-free. After an ensemble of ions fills the storage
region, they are injected orthogonally to the accelerator
column (6) via the application of a pulsed electric field
in the ion storage modulator (5). In the current study, a
pulse frequency of 10 kHz was utilized for which the
effective upper m/z limit was 1000 Da. Ions exit the
accelerating column in the direction of a single-stage
ion mirror (9) with ;4 keV kinetic energy per charge,
traversing a 2.5 m effective flight path before impinging
upon a four-anode detector (8) with two microchannel
plates (Galileo, MA) in a chevron configuration. A four
channel time-to-digital converter (IonWerks, TX) with a
time resolution of 625 ps was used to register all ions
[14]. The pressure in the main TOF chamber was
maintained at ;3 3 1027 torr using a Varian V 550
macro torr turbomolecular pump.
Sample introduction was by continuous infusion at
0.5 mL/min into an electrospray source (1) held at a
potential of ;5 kV. Spectra were accumulated for ;20 s
on standards, but increased to a few minutes on biolog-
ical extracts which produced weaker precursor ion
signals. Initially, a two point external calibration was
performed in order to convert from linear time to linear
mass. External calibrant ions were derived from a
mixture of 2 3 1026 M CsI (m/z 132.9054) and 2 3 1025
M of the octapeptide ALILTLVS (m/z 829.5398). Two
point quadratic external calibration
˛m/z 5 a~t 2 t0! (1)
was performed by calculating the slope a and the offset
t0 (eq 1) using the above two calibrant masses. Single-
point internal recalibration of product ion spectra was
Figure 1. Structure of Bosentan (1) (C27H29N5O6S, [M 1 H]
1 552.1917) and metabolites formed by
oxidation (2) (C27H29N5O7S, [M 1 H]
1 568.1866), demethylation (3) (C26H27N5O6S, [M 1 H]
1
538.1760), and demethylation–oxidation (4) (C26H27N5O7S, [M 1 H]
1 554.1709).
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performed using residual precursor ion signal as the
calibrant. Because only one peak (residual precursor
ion) is used to calculate the value of the slope a, the
value of the offset t0 was taken from the previous
external calibration, because it is less affected by tem-
perature change. All mass assignments were derived
using profiled data centroided (mean mass calculation)
at 50% of the maximum peak height, except where
noted. The counting rate within individual peaks was
constrained to ;10% of the repetition rate of the extrac-
tion pulser in order to avoid peak shape distortions that
can occur at larger intensities due to time-to-digital
converter (TDC) dead time.
Results and Discussion
The initial MS/MS approach to drug metabolite recog-
nition involves the elucidation of product ion structure
from the parent drug. Because similar fragment ions
often dominate both the parent drug and metabolite
spectra, the knowledge gained from the parent drug
fragmentation pathway may be applied to the interpre-
tation of product ion spectra from metabolite precur-
sors. Although it is tempting to assume that product
ions at the same m/z value will have the same structure,
our results show (vide infra) this to be a dangerous
approach in the absence of high resolution data capable
of delivering accurate mass measurements with ,5
ppm error.
QqTOF Product Ion Spectrum of Bosentan
The product ion spectrum of a standard solution of
Bosentan is shown in Figure 3a, and illustrates the
major fragment ions denoted F1–F4. Collision energy
was carefully moderated such that a deliberate amount
of precursor ion current remained after the dissociative
event. Consequently, single-point internal recalibration
of the product ion spectrum could be achieved using
the exact mass of the residual precursor ion, for which
the elemental composition was known [10]. Recali-
brated fragment ion masses and their variation from
previously calculated values based upon known ele-
mental compositions [10] are summarized in Table 1. A
maximum variation across the product ion mass range
of 2 ppm as measured for F1 (m/z 508.1655), demon-
strates the ability to obtain mass accuracies ,5 ppm via
single-point recalibration. Such accuracies are deemed
acceptable for structure elucidation studies when con-
sidering molecules whose molecular weight is ,1000
Da [13].
In the previous investigation concerning the frag-
mentation of Bosentan, the dissociative pathway illus-
trated in Scheme 1 was elucidated, in part, using a
Figure 2. Schematic representation of the QqTOF architecture illustrating the coupling of quadru-
pole 1 (Q), a quadrupole collision cell (q), and a single-stage reflecting time-of-flight analyzer (TOF);
(1) electrospray source, (2) collision cell, (3) focusing grid, (4) slit 2 3 8 mm2, (5) ion storage
modulator, (6) accelerating column, (7) liner, (8) 4-anode detector, (9) ion mirror.
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combination of orifice–skimmer CID and selective CID.
From these studies it was concluded that F4 (m/z 202)
and F3 (m/z 280) were generated from the same precur-
sor ion at m/z 311 (F2). However, subsequent fragmen-
tation of F3 failed to produce m/z 202. Thus, it was
concluded that the formation of F4 was not due to the
consecutive decomposition of F23 F33 F4, but rather
was a competitive pathway preferred over the forma-
tion of F3 from F2 (based upon the relative abundance
ratio of F3:F4). In the current study, the same conclusion
could be reached more readily and assuredly by utiliz-
ing the accurate mass capabilities of the QqTOF.
To appreciate the significance of accurate product
ion mass assignment in structure and fragmentation
elucidation studies, it is important to recognize that
when alternative fragmentation pathways occur, lead-
ing to structures of the same mass but different elemen-
tal composition, the assignment of fragment ion struc-
ture may be ambiguous at nominal mass resolution. For
example, two fragmentation pathways in Scheme 1 are
postulated to rationalize a structure for the ion of
nominal m/z 202. The two elemental compositions
C10H8N3O2 (m/z 202.0617) and C9H8N5O (m/z 202.0729)
have a calculated mass difference of 11.2 mDa (;55
ppm). The measured m/z of F4 (after recalibration) was
202.0725 Da, which clearly allows for the differentiation
of the two fragmentation pathways (and structures)
proposed in Scheme 1. Thus, in one simple experiment,
the current QqTOF results corroborate the pseudo-MS3
results obtained in the previous investigation. Notably,
the successful elucidation of the structure of F4 is
facilitated by an a priori knowledge of the elemental
Figure 3. Product ion spectra of (a) Bosentan (1, [M 1 H]1
552.1917), (b) hydroxy metabolite (2, [M 1 H]1 568.1866), (c)
phenol metabolite (3, [M 1 H]1 538.1760), and (d) hydroxyphenol
metabolite (4, [M 1 H]1 554.1709) after single-point internal reca-
libration with residual precursor ion calibrant.
Table 1. Mass accuracy measurements of Bosentan fragment ions after internal recalibration with residual precursor ion
Fragment Formula Exact mass Measured mass Mass error (mDa)
F1 C25H26N5O5S 508.1655 508.1663 0.8
F2 C15H13N5O3 311.1018 311.1018 0.0
F3 C14H10N5O2 280.0835 280.0835 0.0
F4 C9H8N5O 202.0729 202.0725 0.4
Scheme 1. Proposed fragmentation pathway of Bosentan (1).
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composition of the precursor ion, which may be used to
limit, considerably, the elements from which F4 (or any
of the fragment ions) may be composed. Furthermore,
the number of possible elemental compositions for a
given fragment ion is reduced as the mass accuracy
with which the fragment is measured improves. For
example, given a precursor ion elemental composition
of C27H29N5SO5, only one possible elemental composi-
tion is obtained for fragment ion F4 (C9H8N5O) with a
specified mass accuracy of 5 ppm. When the mass
accuracy for the measurement of F4 is relaxed to 10
ppm, three elemental compositions may be derived:
C8H12NO5, C9H8N5O, and C11H10N2O2. Clearly, a mass
accuracy ,5 ppm is required in order to obtain only one
elemental composition proposal. Such product ion mass
accuracy measurements are only possible by utilizing
an internal calibrant, in this instance the exact mass of
residual precursor ion.
Given both the F4 composition (C9H8N5O) and the
known parent ion structure, it is possible to corroborate
the structure for the F4 fragment with previously re-
ported results which utilized chemical analogs and D2O
exchange [10]. The initial fragmentation study con-
cluded that the F4 fragment ion must contain rings A
and B and the methyl group of ring C, but not the
remainder of ring C where the difference between m/z
311 and m/z 202 corresponded to the loss of a catechol
radical. In order to justify this fragmentation, it was
assumed that initially a radical rearrangement of the
methyl group to the spatially close 5-position of ring B
occurs, creating a distonic ion. In the next step, a
hydrogen atom was rearranged from the methyl group
back to the phenoxy radical formed in the previous
step. Radical cleavage of the bond between ring B and
the oxygen atom of the catechol completed this frag-
mentation step, yielding an even-electron ion and a
catechol radical. The resulting postulated structure had
a theoretical m/z of 202.0729, and appeared to be an ion
with reasonable stability, albeit with aromaticity lost in
ring B. Thus the current QqTOF product ion measure-
ment of F4 (m/z 202.0725) supports the initially postu-
lated fragmentation mechanism.
Product Ion Spectra of Bosentan Metabolites
The major metabolites of Bosentan (Figure 1) are
formed primarily via oxidation (2), demethylation (3),
and a combination of oxidation–demethylation (4). The
product ion spectra of these three major metabolites
were characterized by a common nominal product ion
at m/z 280 (Figure 3b–d). Close inspection of the exact
mass assignment of the m/z 280 fragment ion (after
internal single-point recalibration with the relevant
precursor ion) revealed a mass difference of some 20
mDa between the demethylated metabolites (Figure 3c,
d) and the nondemethylated (oxidized) metabolite (Fig-
ure 3b). The product ion spectrum of Bosentan itself
(Figure 3a) contains a fragment ion at m/z 280.0835,
differing in measured mass from the oxidized analog (4)
by only 0.5 mDa.
The accurate mass assignment of the m/z 280 frag-
ment ion observed in each product ion spectrum of
(2)–(4) suggests that a significant difference exists be-
tween the dissociation pathways of the demethylated
and nondemethylated metabolites. Postulated fragmen-
tation pathways for both nondemethylated (2) and
demethylated (3) metabolites are outlined in Scheme 2a,
b, respectively, and are based upon a number of obser-
vations with respect to the detected metabolite product
ions in Figure 3b–d and the elucidated fragmentation
pathway for Bosentan (Scheme 1). To explain, the
nondemethylated metabolite (2) product ion spectrum
(Figure 3b) shares fragments similar in mass to those
observed for Bosentan (also a nondemethylated precur-
sor), namely fragments F2 (0), F3 (0.5), and F4 (0.1); note
that the number in parentheses refers to the difference
in measured mass (in mDa) between the common
fragment ions of Bosentan and metabolite (2). Thus, the
fragmentation pathway of the nondemethylated metab-
olite (2) appeared to parallel that of Bosentan.
The product ion spectra of the demethylated metab-
olites (Figure 3c, d) notably differed from the spectra of
Bosentan and nondemethylated metabolite (2) by the
presence of an ion at m/z 297.0852. This species is the
proposed demethylated analog of F2, denoted F2A in
Scheme 2b. Based upon the postulated structure for
F2A, a theoretical m/z of 297.0862 may be calculated, a
Scheme 2. Fragmentation pathways for (a) demethylated, and
(b) nondemethylated metabolites of Bosentan as represented by (2)
and (3), respectively.
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difference of only 1.0 mDa (3.4 ppm) from measured
m/z values in Figure 3c, d. Agreement between the
theoretical and measured masses substantiates the
structure proposed for F2A. Further decomposition of
F2A via the loss of NH3 is expected to furnish the
oxygen-containing analog of F3, F3A (theoretical m/z
280.0596). The measured m/z ratios of 280.0628 and
280.0633 for metabolites (3) and (4), respectively, sup-
port the fragmentation pathway for the demethylated
metabolites given in Scheme 2b. However, mass errors
of 3.2 mDa (3) and 3.7 mDa (4) for these measurements
are significantly larger than in all other cases; such
discrepancy is detailed in the section to follow.
The above example demonstrates that the inclination
to extrapolate the parent drug dissociative pathway to
all metabolites is circumvented by the ability to assign
product ion mass with a high degree of accuracy. In the
absence of accurate product ion mass assignment, the
structural differentiation of F3 from F3A would be
impossible, leading to the assumption that both F2 and
F2A intermediates surreptitiously decompose to fur-
nish the identical product ion, F3.
Accurate Mass Measurements from Biological
Extracts
A primary objective of the current investigation was to
evaluate the degree with which interferences from
biological matrices could affect product ion mass accu-
racy. Consequently, crude extracts of plasma were
directly infused, rather than chromatographed, in an
attempt to maximize the probability of either a precur-
sor or product ion interference. Significant suppression
of the molecular ion signal was anticipated, and ob-
served, with this type of sample introduction. Despite
poor ion statistics however, sufficient signal was still
obtained for accurate mass measurements by accumu-
lating spectra for periods of up to 120 s with a Q1
bandpass of ;3 Da.
Although matrix ions were often detected within
0.15 Da of selected precursor ions, TOF resolution
(;8000 m/DmFWHM) was such that unfragmented target
parent ions were adequately differentiated from matrix
interferences, and thus could be used with a high
degree of confidence as internal calibrants. Because
product ion mass accuracy results obtained from me-
tabolite biological extracts matched the previous stan-
dard solution results, effects of product ion interfer-
ences were eliminated.
The product ion spectrum of Bosentan derived from
plasma extract is illustrated in Figure 4a, b, and clearly
demonstrates that the resolution of the TOF instrument
was sufficient to resolve the monoisotopic peak of
Bosentan (m/z 552.1916) from the ion at m/z 552.363, the
latter originating from plasma matrix. In order to de-
termine the reproducibility of TOF mass accuracy mea-
surements, 20 samples of Bosentan and its metabolites
were run over an 8 h period. Of the 20 samples
analyzed, 12 were standards, 4 were plasma extracts,
and 4 were bile extracts. After pooling all data, the
maximum mass error observed (after single-point reca-
libration) for fragments F2, F3, and F4 was 3.4 ppm,
well within acceptable tolerances for elemental compo-
sition determination.
Caveats of Product Ion Exact Mass Measurement
For small molecule structure elucidation (,1000 Da), a
measured mass within 5 ppm of the theoretical mass is
generally accepted as adequate to confirm analyte com-
position [13]. However, circumstances may arise when
the accuracy of exact mass measurement may be com-
promised. These involve occurrences of overlapping
spectral peaks which may result in peak shape distor-
tions such as splitting or peak skew (i.e., peak asymme-
try). Large deviations between measured mass and
theoretical mass may occur when either the precursor
ion or product ion has an unresolved interference.
Precursor ion contamination. If a selected precursor ion
has an unresolved interference, then accurate mass
assignment of the target analyte will be compromised
by an amount dictated largely by the mass of the
analyte and the relative abundance of the interference;
Figure 4. Product ion spectra of Bosentan resulting from direct
infusion of crude plasma extract measured over a mass range of
(a) m/z 50–650 and (b) m/z 551–555.
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the sign of the mass shift (6) depends on whether the
mass of the interference is greater than or less than the
analyte. An unresolved precursor ion can be detrimen-
tal if implemented as a calibrant for its own product ion
spectrum, since the entire mass scale may be altered. In
one instance, when plasma and bile extracts were
infused directly into the mass spectrometer, mass cali-
bration errors of this type were noted. Such a spectrum
from which mass calibration errors were derived is
represented in Figure 5 by a bile extract containing the
parent drug and the three target metabolites. All masses
measured in this spectrum are within 3 ppm from
theoretically predicted values, except for metabolite (4)
(m/ztheor 5 554.1709) which gave a mass error of 8 ppm;
such an error may be attributed to the fact that the
13C2-isotopic peak of Bosentan (m/ztheor 5 554.1984) is
nominally isobaric with the monoisotopic peak of me-
tabolite (4). Notably, the response for Bosentan is about
twice that of metabolite (4) (see Figure 5 inset). Thus the
13C2-isotope contribution from Bosentan is expectedly
significant enough to account for the poor mass accu-
racy associated with the measurement of the monoiso-
topic peak of metabolite (4), thus making the latter
precursor ion unsuitable for recalibration of the corre-
sponding MS/MS spectrum. Appropriately, external
calibration (performed immediately before the MS/MS
experiment) was used for fragment ion mass assign-
ment in the case of metabolite (4).
In many other measurements ions close in exact
mass to the precursor ions of interest were present, but
were sufficiently resolved by the TOF analyzer so as not
to cause a calibration shift.
Product ion contamination. Product ion exact mass mea-
surements may be compromised by the presence of
interfering fragment ions resulting from (a) competitive
fragmentation pathways or (b) the simultaneous frag-
mentation of isobaric precursor ions. Both situations
were observed in the current investigation.
(a) Competitive fragmentation: As previously noted,
m/z ratios of 280.0628 and 280.0633 were obtained for
metabolites (3) and (4), respectively, with mass errors of
3.2 mDa (3) and 3.7 mDa (4) with respect to the
theoretically predicted mass of 280.0596 for fragment
F3A. These “above average” errors support the compet-
itive fragmentation pathway for the demethylated me-
tabolites given in Scheme 2b. To explain, the mecha-
nism for the dissociation of the demethylated
metabolites may be derived from the fact that the
phenol on ring C is a good nucleophile, and thus
represents a driving force for the formation of fragment
F3A via an intramolecular aryl nucleophilic substitution
with elimination of NH3. The competitive fragmenta-
tion pathway leading to the production of F3 from F2A
via the loss of a hydroxyl radical is also suspected to
occur, and may be rationalized from the observed mass
accuracy of ;12 ppm for the measurement of F3A. That
is, an error of ;12 ppm between the theoretical mass of
F3A and the measured m/z ratios of 280.0628 and
280.0633 for metabolites (3) and (4), respectively, is due
to the competitive fragmentation of F2A 3 F3. Al-
though the abundance of F3 relative to F3A was not
possible to ascertain, an error of ;3 mDa in the mea-
surement of F3A suggests only a small contribution
from F3. Comparison of the peak shapes of fragments at
m/z 280 for Bosentan (Figure 6a) and for demethylated
metabolite (3) (Figure 6b) revealed clear differences in
peak width and tailing which confirm the above expla-
nation. In the case of Bosentan and the metabolites
which are not demethylated in ring C, no nucleophilic
substitution is possible and fragment F3 is formed by
loss of the methoxy radical.
(b) Fragmentation of isobaric precursors: In general,
product ion mass measurements may be compromised
by the presence of interfering precursor ions transmit-
ted by Q1, if dissociation of the interfering precursor
affords a product ion spectrum where some species
overlap with those of the analyte. Because Q1 can never
practically transmit a precursor ion at the same resolu-
tion that the TOF analyzer is capable of measuring it,
multiple precursor ions may be passed to the collision
cell, thereby decreasing the selectivity of the MS/MS
technique. Such losses in precursor ion selectivity are
only compounded when a diminution in Q1 resolution
is necessary in order to either enhance sensitivity, or
transmit an isotopic cluster for qualitative purposes.
Despite the shortcomings of limited Q1 selectivity,
desired and undesired precursor ions are likely to be
resolved via the TOF analyzer, thereby alerting the
analyst that the product ion spectrum may be com-
posed of species from a number of different precursor
ions. Note that the presence of multiple precursor ions
for a given Q1 bandpass may be ascertained by operat-
ing in an MS/MS mode, but with a collision energy
which minimizes dissociation.
Figure 5. Crude bile extract containing Bosentan (m/z 552.1907),
hydroxy metabolite (m/z 568.1864), phenol metabolite (m/z
538.1770), and hydroxyphenol metabolite (m/z 554.1754). The inset
demonstrates a response for Bosentan approximately twice that of
the hydroxyphenol metabolite (4).
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The extent of the deleterious effect of mass measure-
ment error due to overlapping product ions from dif-
ferent but isobaric precursor ions was noted in the
current investigation when both Bosentan ([M 1 H]1
m/z 552) and metabolite (4) ([M 1 H]1 m/z 554) were
both present in a biological extract, a situation similar to
that described previously. To explain, the 13C2-isotopic
peak of Bosentan is nominally isobaric with the mo-
noisotopic molecular ion of the demethylated metabo-
lite (4). As a result, both compounds were transmitted
through Q1 (bandpass ;3 Da) when either nominal
monoisotopic mass was selected as a precursor ion.
Thus, although the product ion spectra from the pure
solutions of Bosentan and metabolite (4) were more or
less differentiated by structures F3 (m/z 280.0835) and
F3A (m/z 280.0633) in Figure 6a, b, respectively, such
differentiation in samples containing both precursors
was convoluted. In fact, for the simultaneous dissocia-
tion of 13C2-Bosentan with metabolite (4), the observed
mean m/z of “F3” was 280.0684 Da, an error of 15 mDa
from the theoretical mass of F3, and 8.8 mDa from the
exact mass of F3A. The fact that “F3” in this scenario
was composed of two ions is revealed by the distortion
of the peak as a doublet (Figure 6c). Appropriate
centroiding of each partially resolved peak using the
top 10% of each profile revealed m/z assignments of
280.0647 and 280.0830 Da, data which corroborates the
theoretical m/z of F3A and F3, respectively. Clearly,
Figure 6c demonstrates the current TOF capabilities for
resolving two product ions of equal intensity, separated
in mass by only 23 mDa.
Conclusions
The unique architecture of the QqTOF tandem instru-
ment allowed for the mass measurement of product
ions with an accuracy better than 5 ppm when utilizing
residual precursor ion as a single-point internal cali-
brant. The efficacy with which such mass accuracy may
be applied in the drug metabolism laboratory was
illustrated by the deconvolution of fragmentation path-
ways for both Bosentan and its associated metabolites;
notably, product ion genealogy was established in
instances where low resolution MSn furnished ambigu-
ous results. Accurate mass measurements of the F2
fragment ion from Bosentan corroborated previous re-
sults, albeit in an expedited and less laborious fashion.
Differentiation in the dissociation cascade between de-
methylated and nondemethylated metabolites was pos-
sible based upon accurate mass measurements which
supported the postulated structures for the methylated
product ion analogs of Bosentan (i.e., F2A and F3A).
Clearly, accurate mass assignment at high resolution
allows routine product ion elemental composition and
provides unique opportunities for the automated com-
puter assisted interpretation of CID spectra of drug
biotransformation products.
Accurate product ion mass assignments were possi-
ble from crude plasma or bile extracts, provided the
precursor ion was free of isobaric interferences (or
interferences were resolvable). As these extracts were
introduced via direct infusion, high throughput, exact
mass measurements were feasible, provided sufficient
TOF resolution was available to detect any peak shape
distortion.
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